Download MendeleyFunctional and structural characterization of treatment-emergent nirmatrelvir resistance mutations at low frequencies in the main protease (Mpro) reveals a unique evolutionary route for SARS-CoV-2 to gain resistance.
Deschenes, N.M., Perez-Vargas, J., Zhong, Z., Thomas, M., Kenward, C., Mosimann, W.A., Worrall, L.J., Waglechner, N., Li, A.X., Maguire, F., Aftanas, P., Smith, J.R., Lim, J., Young, R.N., Cherkasov, A., Farooqi, L., Moinuddin, A., Siddiqi, L., Malik, I., Lefebvre, M., Paetzel, M., Strynadka, N.C.J., Jean, F., McGeer, A., Kozak, R.A.(2025) J Infect Dis
- PubMed: 40459233
- DOI: https://doi.org/10.1093/infdis/jiaf294
- Primary Citation of Related Structures:
9PFH, 9PFI - PubMed Abstract:
The main protease (Mpro) is one of the most attractive targets for antiviral drug discovery against SARS-CoV-2. Mutations in Mpro have been linked to resistance against nirmatrelvir-ritonavir (NIR-RIT), an important therapy for SARS-CoV-2 infection. This study aimed to identify low-frequency antiviral resistance mutations in Mpro from NIR-RIT-treated patients and to analyze the enzymatic properties, inhibitor susceptibility, and structural features of new Mpro clinical variants. We screened 1,528 SARS-CoV-2-positive patients from two hospitals and identified 17 who remained positive after treatment. Whole genome sequencing of nasopharyngeal specimens was conducted to identify Mpro clinical variants. The impact of these mutations on Mpro activity and inhibitor susceptibility was investigated using a fluorescent enzymatic biosensor in human cells, along with in vitro thermal stability and structure-based analyses of the Mpro mutants and Mpro-NIR complexes. The analysis identified two novel Mpro clinical variants: D48D/L58F/P132H (variant 1) and D48D/L67V/K90R/P132H (variant 2). Our data show that the selected clinical mutations are localized in the Mpro N-terminal domain, are far from the catalytic site, and strongly impact NIR resistance without affecting Mpro activity. Structural analysis and thermal denaturation analyses revealed that these mutations may disrupt the substrate binding site's structure and dynamics, reducing protein stability and potentially impacting substrate binding or dimerization without compromising catalytic activity. Our new Mpro clinical mutations that confer complete resistance to NIR were not identified during previous cell-culture-based studies. More research is needed to explore resistance mechanisms, providing insights into strategies that mitigate resistance and protect therapeutic efficacy.
- Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada.
Organizational Affiliation:
